Search results for "THERAPY"

showing 10 items of 12482 documents

An RNA toolbox for cancer immunotherapy.

2018

Cancer immunotherapy has revolutionized oncology practice. However, current protein and cell therapy tools used in cancer immunotherapy are far from perfect, and there is room for improvement regarding their efficacy and safety. RNA-based structures have diverse functions, ranging from gene expression and gene regulation to pro-inflammatory effects and the ability to specifically bind different molecules. These functions make them versatile tools that may advance cancer vaccines and immunomodulation, surpassing existing approaches. These technologies should not be considered as competitors of current immunotherapies but as partners in synergistic combinations and as a clear opportunity to r…

0301 basic medicineSequence analysismedicine.medical_treatmentComputational biologyBiologyCancer VaccinesCell therapyImmunomodulation03 medical and health sciencesImmune systemCancer immunotherapyNeoplasmsDrug DiscoveryGene expressionmedicineAnimalsHumansPharmacologyRegulation of gene expressionRNACancerGeneral Medicinemedicine.disease030104 developmental biologyRNARNA InterferenceImmunotherapyNature reviews. Drug discovery
researchProduct

Wharton’s Jelly Mesenchymal Stromal Cells from Human Umbilical Cord: a Close-up on Immunomodulatory Molecules Featured In Situ and In Vitro

2019

Therapeutic options for end-stage organ failure are often limited to whole organ transplantation. The tolerance or rejection of the transplanted organ is driven by both early non-specific innate and specific adaptive responses. The use of mesenchymal stromal cells (MSCs) is considered a promising tool in regenerative medicine. Human umbilical cord (HUC) is an easily available source of MSCs, without relevant ethical issues. Moreover, Wharton's jelly-derived MSCs (WJ-MSCs), showed consistent immunomodulatory features that may be useful to promote immune tolerance in the host after transplantation. Few data are available on the phenotype of WJ-MSCs in situ. We investigated the expression of i…

0301 basic medicineSettore BIO/17 - IstologiaB7 AntigensT cellIn Vitro TechniquesBiologyLymphocyte ActivationRegenerative medicineCell therapyUmbilical CordImmune toleranceImmunomodulation03 medical and health sciences0302 clinical medicineWharton's jellymedicineHumansWharton JellyCD276Cells CulturedCell ProliferationStem cellMesenchymal stem cellCell DifferentiationMesenchymal Stem CellsHuman umbilical cordCell biologyTransplantationTolerance induction030104 developmental biologymedicine.anatomical_structureB7-H3030220 oncology & carcinogenesisLymphocyte inhibitionRegenerative medicineCytokinesWharton’s jelly mesenchymal stromal cellsStem cell
researchProduct

Immunomodulatory effects of stem cells: Therapeutic option for neurodegenerative disorders.

2017

Stem cells have the capability of self-renewal and can differentiate into different cell types that might be used in regenerative medicine. Neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS) currently lack effective treatments. Although stem cell therapy is still on the way from bench to bedside, we consider that it might provide new hope for patients suffering with neurodegenerative diseases. In this article, we will give an overview of recent studies on the potential therapeutic use of mesenchymal stem cells (MSCs), neural stem cells (NSCs), embryonic stem cells (ESCs), induced pluripotent…

0301 basic medicineSettore BIO/17 - IstologiaPathologymedicine.medical_specialtymedicine.medical_treatmentRegenerative medicineModels Biological03 medical and health sciencesmedicineAnimalsHumansImmunologic FactorsInduced pluripotent stem cellPharmacologyStem cell therapybusiness.industryMultiple sclerosisStem CellsMesenchymal stem cellNeurodegenerative DiseasesGeneral MedicineStem-cell therapyNeurodegenerative disordermedicine.diseaseEmbryonic stem cellNeural stem cell030104 developmental biologyRegenerative medicineStem cellbusinessNeuroscienceStem Cell TransplantationBiomedicinepharmacotherapy = Biomedecinepharmacotherapie
researchProduct

Gut microbiota and cancer: How gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy

2019

Gut microbiota is involved in gastrointestinal carcinogenesis. Also, it modulates the activity, efficacy and toxicity of several chemotherapy agents, such as gemcitabine, cyclophosphamide, irinotecan, cisplatin and 5-Fluorouracil, and target therapy, such as tyrosine kinase inhibitors. More recently, accumulating data suggest that the composition of gut microbiota may also affect efficacy and toxicity of cancer immunotherapy. Therefore, the manipulation of gut microbiota through antibiotics, probiotics, prebiotics or fecal transplantation has been investigating with the aim to improve efficacy and mitigate toxicity of anticancer drugs.

0301 basic medicineSettore MED/06 - Oncologia Medicamedicine.drug_class5-Fluorouracilmedicine.medical_treatmentAntibioticsAntineoplastic AgentsImmune checkpoint inhibitorGut floraPharmacologyIrinotecandigestive systemImmune checkpoint inhibitors03 medical and health sciences0302 clinical medicineCancer immunotherapyNeoplasmsmedicineAnimalsHumansCyclophosphamide5-Fluorouracil; Cisplatin; Cyclophosphamide; Gemcitabine; Immune checkpoint inhibitors; Irinotecan; Microbiota; Tyrosine kinase inhibitorsTyrosine kinase inhibitorsChemotherapybiologybusiness.industryMicrobiotaCancerHematologyFecal Microbiota Transplantationbiology.organism_classificationmedicine.diseaseGemcitabineGemcitabineGastrointestinal MicrobiomeIrinotecan030104 developmental biologyOncology030220 oncology & carcinogenesisToxicityImmunotherapyCisplatinbusinessmedicine.drugCritical Reviews in Oncology/Hematology
researchProduct

Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential

2018

Abstract: Introduction: Pancreatic neuroendocrine tumors (pNETs) represent a small part of pancreatic neoplasms, and the knowledge about their indolent clinical course remains a subject of investigation. They occur sporadically or as part of familial cancer syndromes and are classified by WHO in 3 categories. There is ongoing research to understand their molecular profiling and leading mutations.Areas covered: The aim of this review is to clarify the overall aspects of tumorigenesis, to expose the latest developments in understanding the course of the disease and the possible therapeutic implications of these. The review also discusses functional and non-functional pNETs and associated inhe…

0301 basic medicineSettore MED/06 - Oncologia Medicamedicine.medical_treatmentClinical Decision-MakingAntineoplastic AgentsDiseaseNeuroendocrine tumorsBioinformaticsTargeted therapy03 medical and health sciences0302 clinical medicinePredictive Value of TestsFunctional tumorBiomarkers TumormedicineHumansProfiling (information science)Molecular Targeted Therapyneurondocrine tumorPrecision MedicineTherapeutic strategymolecular pathwayHepatologybusiness.industryGene Expression ProfilingGastroenterologyClinical coursehereditary syndrometargeted therapymedicine.diseaseGene Expression Regulation NeoplasticPancreatic NeoplasmsNeuroendocrine Tumors030104 developmental biology030220 oncology & carcinogenesispancreatic tumorFamilial CancerHuman medicinebusinessSignal TransductionExpert review of gastroenterology & hepatology
researchProduct

Clinical Characteristics and Outcomes of Patients with COVID-19 Infection: The Results of the SARS-RAS Study of the Italian Society of Hypertension

2021

: The COVID-19 infection has rapidly spread around the world and a second wave is sweeping in many countries. Different clinical and epidemiological aspects characterize the disease and their understanding is necessary to better face the management of the pandemic in progress. The Italian society of arterial hypertension with the SARS-RAS study has contributed significantly to the knowledge of the interaction between inhibition of the renin-angiotensin system and COVID-19 infection. Furthermore, the study results help to understand some of the main aspects related to mortality and morbidity deriving from the infection through a multicentre analysis throughout the national territory.

0301 basic medicineSettore MED/09 - Medicina InternaCross-sectional studyDiseaseComorbiditySeverity of Illness IndexComorbiditiesRenin-Angiotensin System0302 clinical medicineRisk FactorsSex-differences.EpidemiologyPandemicFrailtySars-Cov2Treatment OutcomeItalyAnti-hypertensive therapy; comorbidities; frailty; Sars-Cov2; sex-differencesHypertensionComorbiditiePosition PaperRisk assessmentCardiology and Cardiovascular Medicinemedicine.medical_specialtySex-differenceRisk Assessment03 medical and health sciencesPharmacotherapySex FactorsSeverity of illnessmedicineAnti-hypertensive therapy Sars-Cov2 Frailty Comorbidities Sex-differencesInternal MedicineHumansArterial PressureAnti-hypertensive therapy Comorbidities Frailty Sars-Cov2 Sex-differencesIntensive care medicineAnti-hypertensive therapyAntihypertensive AgentsAnti-hypertensive therapy; Comorbidities; Frailty; Sars-Cov2; Sex-differences; Antihypertensive Agents; Arterial Pressure; COVID-19; Comorbidity; Cross-Sectional Studies; Frailty; Humans; Hypertension; Italy; Renin-Angiotensin System; Risk Assessment; Risk Factors; Severity of Illness Index; Sex Factors; Treatment OutcomeSettore MED/14 - Nefrologiabusiness.industryCOVID-19medicine.diseaseComorbiditySex-differences030104 developmental biologyCross-Sectional Studiesbusiness030217 neurology & neurosurgery
researchProduct

PACAP38 and PAC1 receptor blockade: a new target for headache?

2018

Abstract Pituitary adenylate cyclase activating polypeptide-38 (PACAP38) is a widely distributed neuropeptide involved in neuroprotection, neurodevelopment, nociception and inflammation. Moreover, PACAP38 is a potent inducer of migraine-like attacks, but the mechanism behind this has not been fully elucidated. Migraine is a neurovascular disorder, recognized as the second most disabling disease. Nevertheless, the antibodies targeting calcitonin gene-related peptide (CGRP) or its receptor are the only prophylactic treatment developed specifically for migraine. These antibodies have displayed positive results in clinical trials, but are not effective for all patients; therefore, new pharmacol…

0301 basic medicineSide effectPAC1 receptorMigraine DisordersMigraine Disorders/drug therapylcsh:MedicinePituitary Adenylate Cyclase-Activating Polypeptide/antagonists & inhibitorsReview ArticleTriptansPharmacologyCalcitonin gene-related peptidePACAPNeuroprotectionmigraine; PAC1 receptor; PACAP; prophylactic treatment; animals; disease models animal; headache; humans; migraine disorders; pituitary adenylate cyclase-activating polypeptide; receptors pituitary adenylate cyclase-activating polypeptide type I; neurology (clinical); anesthesiology and pain medicine03 medical and health sciences0302 clinical medicineAnimalsHumansMedicineMigraine treatmentReceptorMigraineHeadache/drug therapybusiness.industrylcsh:RHeadacheGeneral Medicinemedicine.disease3. Good healthBlockadeDisease Models Animal030104 developmental biologyAnesthesiology and Pain MedicineMigrainePituitary Adenylate Cyclase-Activating PolypeptideNeurology (clinical)businessProphylactic treatment030217 neurology & neurosurgeryReceptors Pituitary Adenylate Cyclase-Activating Polypeptide Type IReceptors Pituitary Adenylate Cyclase-Activating Polypeptide Type I/antagonists & inhibitorsmedicine.drugJournal of Headache and Pain
researchProduct

GSK-3 in liver diseases: Friend or foe?

2020

Liver diseases, including hepatitis due to hepatitis B or C virus infection, non-alcoholic fatty liver disease, and hepatocellular carcinoma pose major challenges for overall health due to limited curative treatment options. Thus, there is an urgent need to develop new therapeutic strategies for the treatment of these diseases. A better understanding of the signaling pathways involved in the pathogenesis of liver diseases can help to improve the efficacy of emerging therapies, mainly based on pharmacological approaches, which influence one or more specific molecules involved in key signal transduction pathways. These emerging therapies are very promising for the prevention and treatment of …

0301 basic medicineSignaling pathwaysDruggabilityDiseaseBioinformaticsNon-alcoholic fatty liver disease (NAFLD)Glycogen Synthase Kinase 303 medical and health sciences0302 clinical medicineGSK-3Glycogen synthase kinase 3 (GSK-3)AnimalsHumansMedicineHepatitis B virus (HBV)Molecular Targeted TherapyEnzyme InhibitorsHepatocellular carcinoma (HCC)Molecular BiologyHepatitisbusiness.industryLiver DiseasesFatty liverDisease ManagementHepatitis C virus (HCV)Cell BiologyHepatitis Bmedicine.disease030104 developmental biologyGene Expression RegulationMultigene Family030220 oncology & carcinogenesisHepatocellular carcinomaHost-Pathogen InteractionsDisease SusceptibilitySignal transductionbusinessBiomarkersSignal TransductionBiochimica et Biophysica Acta (BBA) - Molecular Cell Research
researchProduct

Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning.

2021

Coronavirus disease 2019 (COVID-19) is a major threat worldwide due to its fast spreading. As yet, there are no established drugs available. Speeding up drug discovery is urgently required. We applied a workflow of combined in silico methods (virtual drug screening, molecular docking and supervised machine learning algorithms) to identify novel drug candidates against COVID-19. We constructed chemical libraries consisting of FDA-approved drugs for drug repositioning and of natural compound datasets from literature mining and the ZINC database to select compounds interacting with SARS-CoV-2 target proteins (spike protein, nucleocapsid protein, and 2′-o-ribose methyltransferase). Supported by…

0301 basic medicineSimeprevirArtificial intelligencevirusesMERS Middle East Respiratory SyndromeHealth InformaticsBiologyMachine learningcomputer.software_genremedicine.disease_causeAntiviral AgentsArticleWHO World Health OrganizationAUC area under the curve03 medical and health sciences0302 clinical medicinessRNA single-stranded RNA virusmedicineChemotherapyHumansSARS severe acute respiratory syndromeCOVID-19 coronavirus disease 2019CoronavirusNatural productsVirtual screeningACE2 angiotensin converting enzyme 2Drug discoverybusiness.industrySARS-CoV-2COVID-19LBE lowest binding energyFDA Food and Drug AdministrationROC receiver operating characteristicComputer Science ApplicationsHIV human immunodeficiency virusMolecular Docking SimulationDrug repositioning030104 developmental biologyDrug developmentSevere acute respiratory syndrome-related coronavirusParitaprevirInfectious diseasesRespiratory virusArtificial intelligenceSupervised Machine Learningbusinesscomputer030217 neurology & neurosurgeryComputers in biology and medicine
researchProduct

Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program

2019

AbstractWe reported the efficacy and safety data for daclatasvir (DCV)-based all-oral antiviral therapy in patients treated in the Italian compassionate-use program. 275 patients were included (202 male-73.5%, mean age: 57.4 years, 62 HIV-coinfected, 94 with recurrence of hepatitis C post-OLT). Forty-nine patients (17.8%) had Child-Pugh B, Genotype(G) distribution was: G1a:72 patients (26.2%), G1b:137 (49.8%); G3:40 (14.5%) and G4:26 (9.5%). Patients received DCV with sofosbuvir(SOF) (n = 221, 129 with ribavirin(RBV) or with simeprevir (SMV) or asunaprevir (ASU) (n = 54, 19 with RBV) for up to 24 weeks. Logistic regression was used to identify baseline characteristics associated with sustai…

0301 basic medicineSimeprevirLiver CirrhosisMalePyrrolidinesSofosbuvirSustained Virologic Responselcsh:MedicineSettore MED/05Gastroenterologychemistry.chemical_compound0302 clinical medicineLiver Function TestsINFECTIONMedicinePLUS SOFOSBUVIRlcsh:ScienceSulfonamidesMultidisciplinaryImidazolesValineHepatitis CMiddle AgedTreatment OutcomeItalySAFETYHCVSUSTAINED VIROLOGICAL RESPONSEDrug Therapy CombinationFemaleRIBAVIRINSettore BIO/19 - MICROBIOLOGIA GENERALECHRONIC HEPATITIS-Cmedicine.drugAdultmedicine.medical_specialtyDaclatasvirDrug-Related Side Effects and Adverse ReactionsAntiviral AgentsArticle03 medical and health sciencesInternal medicineHumansAgedADVANCED LIVER-DISEASEbusiness.industryRibavirinVIRUS GENOTYPE 3lcsh:RHepatitis C ChronicHCV HIV Daclatasvirmedicine.diseaseIsoquinolinesEFFICACYRegimen030104 developmental biologychemistryAsunaprevirlcsh:QLiver functionCarbamatesSofosbuvirbusiness030217 neurology & neurosurgeryScientific Reports
researchProduct